The development of highly active anti-retroviral therapy with protease inhibitors (PIs) has been associated with metabolic abnormalities including disturbances in glucose metabolism, dyslipidemia, and fat distribution/lipodystrophy. However their cause is debated. Data show that not all of the metabolic effects of PIs are direct toxic effects, as some are due to restoration to health, reconstitution of immune system or changes in fat distribution. A role for NRTI is emerging. To design future HIV drugs that have the least metabolic effects it is necessary to determine which metabolic effects of these drugs are direct toxic drug effects vs. secondary to changes in disease status. Given the difficulty in dissecting out the different contributors in HIV-positive patients, we have begun studies of the metabolic effects of ARV in HIV-negative controls. We have evidence that the metabolic effects are drug-specific and not class-specific with independent effects of PIs on glucose and lipid metabolism. Our preliminary data suggest that PIs affect several pathways in glucose metabolism including peripheral insulin resistance, insulin secretion and hepatic glucose production. These three lesions are key contributors to the development of type 2 diabetes. Therefore we propose to test the effects of PIs and NRTIs as follows:
Specific Aim 1 a: To determine which Pls inhibit insulin secretion in humans.
Specific Aim 1 b: To determine which PIs acutely block insulin mediated glucose disposal in humans.
Specific Aim 1 c: To determine which PIs increase hepatic glucose production and to determine the mechanisms by quantifying gluconeogenesis and glycogenolysis.
Specific Aim 2 a: To demonstrate that in subjects with elements of Metabolic Syndrome compared to thin healthy controls, PIs induce more diabetes and impaired glucose tolerance on oral glucose tolerance testing.
Specific Aim 2 b: To determine if the effects of PIs in Metabolic Syndrome are more severe at the level of resistance to insulin-mediated glucose disposal, insulin secretion and hepatic glucose production.
Specific Aim 3 a: To demonstrate that NRTI combinations, alone or with a PI, affect glucose metabolism in HIV negative subjects using the OGTT in acute or four-week studies.
Specific Aim 3 b: To determine the mechanisms by which NRTI adversely affect glucose metabolism, we will assess their effects on insulin mediated glucose disposal, insulin secretion and/or hepatic glucose production.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK066999-01
Application #
6745782
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Pawlyk, Aaron
Project Start
2004-03-01
Project End
2007-12-31
Budget Start
2004-03-01
Budget End
2004-12-31
Support Year
1
Fiscal Year
2004
Total Cost
$371,250
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Rao, Madhu N; Mulligan, Kathleen; Tai, Viva et al. (2010) Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. J Clin Endocrinol Metab 95:4361-6
Grunfeld, Carl (2010) Dyslipidemia and its Treatment in HIV Infection. Top HIV Med 18:112-8
Pao, Vivian Y; Lee, Grace A; Taylor, Steven et al. (2010) The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS 24:265-70
Delaney, Joseph A C; Scherzer, Rebecca; Biggs, Mary L et al. (2010) Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 24:2201-9
Taylor, Steven A; Lee, Grace A; Pao, Vivian Y et al. (2010) Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr 55:361-4
Lee, Grace A; Schwarz, Jean-Marc; Patzek, Sophie et al. (2009) The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. J Acquir Immune Defic Syndr 52:246-8
Mulligan, Kathleen; Khatami, Hootan; Schwarz, Jean-Marc et al. (2009) The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 94:1137-44
Pao, Vivian; Lee, Grace A; Grunfeld, Carl (2008) HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 10:61-70
Lee, Grace A; Rao, Madhu; Mulligan, Kathleen et al. (2007) Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 21:2183-90
Lee, Grace A; Lo, Joan C; Aweeka, Francesca et al. (2006) Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 43:658-60

Showing the most recent 10 out of 13 publications